Krystexxa and Zantac drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Krystexxa (pegloticase) and Zantac (ranitidine hydrochloride). Common drug interactions include arteriovenous malformation among females and therapeutic response decreased among males.

The phase IV clinical study analyzes what interactions people have when they take Krystexxa and Zantac. It is created by eHealthMe based on reports of 15 people who take the same drugs from the FDA, and is updated regularly.

What is Krystexxa?

Krystexxa has active ingredients of pegloticase. eHealthMe is studying from 2,548 Krystexxa users. Check the latest studies of Krystexxa.

What is Zantac?

Zantac has active ingredients of ranitidine hydrochloride. It is often used in gastroesophageal reflux disease. eHealthMe is studying from 434,161 Zantac users. Check the latest studies of Zantac.

On Jul, 06, 2026

15 people who take Krystexxa and Zantac together, and have interactions are studied.

What are the common drug interactions of Krystexxa and Zantac, by gender? *:

female:

Arteriovenous malformation
Upper gastrointestinal haemorrhage (upper gastrointestinal bleeding)
Gout (uric acid crystals building up in the body)
Infusion related reaction
Rash

male:

Therapeutic response decreased (less preventive response)
Infusion related reaction
Ear discomfort
Fall
Fracture displacement
Gait disturbance
Hypoaesthesia (reduced sense of touch or sensation)
Infusion site extravasation (flow of (blood or lymph) from infusion site)
Injection site pain
Injection site swelling

What are the common drug interactions of Krystexxa and Zantac, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

Infusion related reaction
Therapeutic response decreased (less preventive response)

40-49:

Infusion related reaction
Rash
Anaphylactic reaction (serious allergic reaction)
Therapeutic response decreased (less preventive response)

50-59:

Infusion related reaction
Therapeutic response decreased (less preventive response)
Ankle fracture
Arthralgia (joint pain)
Back pain
Blood glucose increased
Chest discomfort
Fall
Fracture displacement
Gait disturbance

60+:

Arteriovenous malformation
Upper gastrointestinal haemorrhage (upper gastrointestinal bleeding)
Acute myocardial infarction (acute heart attack)
Ear discomfort
Hypoaesthesia (reduced sense of touch or sensation)
Infusion site extravasation (flow of (blood or lymph) from infusion site)
Injection site pain
Injection site swelling
Pain
Poor peripheral circulation

What are the existing conditions these people have? *

Gout (uric acid crystals building up in the body): 14 people, 93.33%
Allergies: 6 people, 40.00%
High Blood Pressure: 3 people, 20.00%
Type 2 Diabetes: 2 people, 13.33%
Paronychia (infection in the tissues adjacent to a nail on a finger or toe): 2 people, 13.33%
Joint Pain: 2 people, 13.33%
Depression: 2 people, 13.33%
Cardiac Failure Congestive: 2 people, 13.33%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 2 people, 13.33%
Seasonal Allergy (allergic condition due to certain season): 1 person, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Krystexxa and Zantac?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously